CLNN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Clene Inc (CLNN) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong positive catalysts, including promising FDA-related developments, analyst upgrades, and a robust pipeline for ALS treatment. Despite weak financial performance, the company's strategic initiatives and potential for accelerated approval make it a compelling long-term investment.
The MACD is positive and expanding (0.183), indicating bullish momentum. RSI is at 78.727, suggesting the stock is nearing overbought territory but not yet signaling a reversal. Moving averages are converging, and the stock is trading near its resistance level of 5.252, showing potential for a breakout. Overall, the technical indicators suggest a positive trend.
Completion of FDA-recommended biomarker analyses for CNM-Au8, showing statistically significant results.
Analyst upgrade with a price target increase from $20 to $
Oversubscribed $28 million direct offering, extending operational funding into Q4
Plans for a Type C FDA meeting and Phase 3 RESTORE-ALS trial in
CNM-Au8's demonstrated survival benefits in ALS patients, supporting accelerated approval.
Weak financial performance in Q3 2025, with revenue dropping 82.76% YoY and EPS declining 30.33% YoY.
Post-market price decline of -2.32%, indicating some short-term selling pressure.
In Q3 2025, revenue dropped significantly (-82.76% YoY) to $15,000, and EPS declined by -30.33% YoY to -0.85. However, net income improved slightly (-9.90% YoY), and gross margin increased by 26.09% to 100%. The financials reflect operational challenges but also improved cost management.
Maxim analyst Naz Rahman upgraded the stock with a price target increase from $20 to $30, citing significant progress in FDA-recommended biomarker analyses and the potential for NDA filing for CNM-Au8.
